David R. Strayer is Chief Science/Medical Officer at HEMISPHERX BIOPHARMA INC (HEB). They have made 8 open-market trades across 1 company since 2008, most recently 2019-06-21.
CIK 0001270074
7 open-market purchases totalling $183K since 2008, against 1 sale. Across 6 scored buys the stock is down 4.7% at ninety days, and 5.7 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| HEB | 5,420 | $10K |
Shares reported on the most recent Form 4, priced at the 2019-06-25 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 14% | 14% | 17% |
| Avg Move | -8.7% | -7.7% | -4.7% |
| Alpha | -5.8% | -8.4% | -5.7% |
| Scored | 7 | 7 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| HEB | BUY | 2019-06-21 | 2019-06-25 | $4.03 | $10K | -10.6% | -37.6% | N/A |
| HEB | BUY | 2017-05-02 | 2017-05-02 | $0.63 | $5K | -3.1% | -19.1% | -35.3% |
| HEB | BUY | 2017-02-16 | 2017-02-21 | $0.46 | $5K | +6.4% | +12.8% | +17.0% |
| HEB | BUY | 2012-05-17 | 2012-05-21 | $0.26 | $13K | -13.3% | -2.5% | -2.5% |
| HEB | SELL | 2010-06-22 | 2010-06-24 | $0.55 | $28K | -13.3% | -2.5% | -2.5% |
| HEB | BUY | 2010-06-16 | 2010-06-18 | $0.58 | $134K | -13.3% | -2.5% | -2.5% |
| HEB | BUY | 2009-12-07 | 2009-12-08 | $0.57 | $7K | -13.3% | -2.5% | -2.5% |
| HEB | BUY | 2008-09-25 | 2008-10-06 | $0.35 | $10K | -13.3% | -2.5% | -2.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.